Ganglionic Blocking Drugs and Nicotine
... Although a number of drugs possessing ganglionic blocking properties have been developed, at the present time they are rarely used clinically. Other drugs, such as curare, are not employed as ganglionic blocking agents, although they block ganglionic nicotinic receptors, especially at high doses. Th ...
... Although a number of drugs possessing ganglionic blocking properties have been developed, at the present time they are rarely used clinically. Other drugs, such as curare, are not employed as ganglionic blocking agents, although they block ganglionic nicotinic receptors, especially at high doses. Th ...
Mechanism of Actions of Antidepressants: Beyond the Receptors
... Since the discovery of first antidepressants-monoamine oxidase inhibitors- a half century passed. There are now almost twodozen antidepressant agents that work by nine distinct pharmacological mechanisms at the receptor level. However, opposite to the divergence in their pharmacological mechanisms a ...
... Since the discovery of first antidepressants-monoamine oxidase inhibitors- a half century passed. There are now almost twodozen antidepressant agents that work by nine distinct pharmacological mechanisms at the receptor level. However, opposite to the divergence in their pharmacological mechanisms a ...
Potent synthetic cannabinoid smoking mixtures
... The vast majority of the market is made up of pre-packaged branded products. These branded products contain a non-psychoactive dried plant base that has been dipped or sprayed with one or more of a range of synthetic cannabinoids. Some of these products are marketed as ‘ultra potent’ [2]. There are ...
... The vast majority of the market is made up of pre-packaged branded products. These branded products contain a non-psychoactive dried plant base that has been dipped or sprayed with one or more of a range of synthetic cannabinoids. Some of these products are marketed as ‘ultra potent’ [2]. There are ...
Immunosuppressants 2
... • It is usually given to the mother within 72 hours after the birth of Rh-positive baby • This would prevent hemolytic anemia that may occur in subsequent pregnancies • Adverse Effects: ...
... • It is usually given to the mother within 72 hours after the birth of Rh-positive baby • This would prevent hemolytic anemia that may occur in subsequent pregnancies • Adverse Effects: ...
16ppt
... --------------------------------Side effects include drowsiness (often limiting), increased appetite and weight gain ...
... --------------------------------Side effects include drowsiness (often limiting), increased appetite and weight gain ...
Body Temperature and Analgesic Effects of Selective Mu and Kappa
... et al., 1988). However, it was not known whether the same effects would occur when those agonists or antagonists were administered directly into the POAH, a vital region in Tb regulation, rather than by the i.c.v. route, which allows the drugs to diffuse rapidly throughout the brain. The POAH is gen ...
... et al., 1988). However, it was not known whether the same effects would occur when those agonists or antagonists were administered directly into the POAH, a vital region in Tb regulation, rather than by the i.c.v. route, which allows the drugs to diffuse rapidly throughout the brain. The POAH is gen ...
Respiratory Pharmacology
... – Interactions: caffeine, Tagamet, fluoroquinolones, other CNS drugs ...
... – Interactions: caffeine, Tagamet, fluoroquinolones, other CNS drugs ...
Diphenhydramine (Benadryl)
... Diphenhydramine demonstrates both stimulant and depressant effects on the central nervous system although stimulation is only occasionally seen in patients given conventional doses with accompanying restlessness, nervousness and inability to sleep. Companies have capitalized on the depressant effect ...
... Diphenhydramine demonstrates both stimulant and depressant effects on the central nervous system although stimulation is only occasionally seen in patients given conventional doses with accompanying restlessness, nervousness and inability to sleep. Companies have capitalized on the depressant effect ...
cHAPTER 7 The specificity of different selective and non
... unwanted effects of existing benzodiazepines. There are two options to attain this selectivity: selective affinity and selective efficacy for a certain subtype. The first option first resulted in sleep inducers with a higher affinity for the α1 receptor subtype (e.g. zolpidem, zaleplon) [28]. More recent ...
... unwanted effects of existing benzodiazepines. There are two options to attain this selectivity: selective affinity and selective efficacy for a certain subtype. The first option first resulted in sleep inducers with a higher affinity for the α1 receptor subtype (e.g. zolpidem, zaleplon) [28]. More recent ...
2. Virtual Screening of Molecular Properties and Bioactivity Score of
... Results and Discussion The calculated values of various parameters of the isolated compounds for drug likeness are presented in the table 1. Drug likeness evaluates whether a particular molecule is similar to the known drug or not. It is a complex balance of various properties and structural feature ...
... Results and Discussion The calculated values of various parameters of the isolated compounds for drug likeness are presented in the table 1. Drug likeness evaluates whether a particular molecule is similar to the known drug or not. It is a complex balance of various properties and structural feature ...
No Slide Title - Open.Michigan
... Copyright holders of content included in this material should contact [email protected] with any questions, corrections, or clarification regarding the use of content. For more information about how to cite these materials visit http://open.umich.edu/education/about/terms-of-use. Any medical i ...
... Copyright holders of content included in this material should contact [email protected] with any questions, corrections, or clarification regarding the use of content. For more information about how to cite these materials visit http://open.umich.edu/education/about/terms-of-use. Any medical i ...
Urinary Incontinence Drugs
... ADRs – same as others, but less severs. Less CNS effects b/c does not cross blood brain barrier (especially solifenacin). DDis – CYP450 substrate ...
... ADRs – same as others, but less severs. Less CNS effects b/c does not cross blood brain barrier (especially solifenacin). DDis – CYP450 substrate ...
PCP & Ketamine
... Principal molecular target for both is NMDA receptor NMDA is an important ionotropic receptor for glutamate Both are noncompetitive antagonists They block the receptor at a different site than the site at which NMDA or glutamate binds NMDA plays a role in glutamate signaling Cerebral cortex and hipp ...
... Principal molecular target for both is NMDA receptor NMDA is an important ionotropic receptor for glutamate Both are noncompetitive antagonists They block the receptor at a different site than the site at which NMDA or glutamate binds NMDA plays a role in glutamate signaling Cerebral cortex and hipp ...
Synthetic Cannabinoids
... Potency and blend: Different brands of synthetic cannabinoid smoking mixtures can have profoundly different effects22. Although there are reported differences in the subjective effect of various synthetic cannabinoid compounds, the potency of any brand appears to owe more to the ratio of inert plant ...
... Potency and blend: Different brands of synthetic cannabinoid smoking mixtures can have profoundly different effects22. Although there are reported differences in the subjective effect of various synthetic cannabinoid compounds, the potency of any brand appears to owe more to the ratio of inert plant ...
Slides - American Chemical Society
... But the brain has a great need for nutrients and oxygen (it has a high blood flow), which increases the risk of toxic danger Solution = the blood-brain barrier (BBB) Capillaries in brain do not allow drugs to pass as easily as capillaries in rest of body ...
... But the brain has a great need for nutrients and oxygen (it has a high blood flow), which increases the risk of toxic danger Solution = the blood-brain barrier (BBB) Capillaries in brain do not allow drugs to pass as easily as capillaries in rest of body ...
5-Hypoglycemic drugs..
... in the liver by decreasing excessive, glucose production, most likely via reduced gluconeogenesis resulting from an increased sensitivity to insulin. • They also improve glucose utilization by restoring tissue sensitivity to insulin • They appear to have their main action in the liver mitochondria v ...
... in the liver by decreasing excessive, glucose production, most likely via reduced gluconeogenesis resulting from an increased sensitivity to insulin. • They also improve glucose utilization by restoring tissue sensitivity to insulin • They appear to have their main action in the liver mitochondria v ...
Pharmacology-Drugs For Parkinson
... 3. Antipsychotics, BDZ, phenytoin may inhibit antiparkinsonism effects 4. Food-drug interaction 5. high protein meals may compete with amino acid transport of levodopa across BBB vii. Dosage forms 1. Available PO as immediate release or sustained release. Dose provided as mg of Carbidopa/mg of Levod ...
... 3. Antipsychotics, BDZ, phenytoin may inhibit antiparkinsonism effects 4. Food-drug interaction 5. high protein meals may compete with amino acid transport of levodopa across BBB vii. Dosage forms 1. Available PO as immediate release or sustained release. Dose provided as mg of Carbidopa/mg of Levod ...
patrick_tb_ch05
... 01) Which of the following statements is not true about receptors? Feedback: Some protein receptors are certainly present inside cells, but the majority are present in the cell membrane. The binding site of receptors is analogous to the active site of enzymes. However, no reaction is catalysed. The ...
... 01) Which of the following statements is not true about receptors? Feedback: Some protein receptors are certainly present inside cells, but the majority are present in the cell membrane. The binding site of receptors is analogous to the active site of enzymes. However, no reaction is catalysed. The ...
10 Pharmacologic Management Of Parkinsonism
... dopamine-receptor proteins • All the dopamine receptors are heptahelical G protein-coupled receptors (GPCRs) • Five dopamine receptors have been identified, and they fall into two groups on the basis of their pharmacological and structural properties: • D1-like receptors (D1 & D5) • D2-like receptor ...
... dopamine-receptor proteins • All the dopamine receptors are heptahelical G protein-coupled receptors (GPCRs) • Five dopamine receptors have been identified, and they fall into two groups on the basis of their pharmacological and structural properties: • D1-like receptors (D1 & D5) • D2-like receptor ...
Intrathecal Narcotics for Post
... Evidence Based Practice • What types of surgery is amenable to intrathecal narcotics? • What doses should we use? • What outcomes can we affect? ...
... Evidence Based Practice • What types of surgery is amenable to intrathecal narcotics? • What doses should we use? • What outcomes can we affect? ...
5F-APINACA (5F-AKB-48) Review Report
... 5F-APINACA belongs to the synthetic cannabinoid receptor agonists (SCRAs), which have affinity for CB1 and CB2 receptors12 with activation of the former accounting for the psychoactivity of these substances.13 While its molecular structure differs only slightly from that of AKB-48 by the addition of ...
... 5F-APINACA belongs to the synthetic cannabinoid receptor agonists (SCRAs), which have affinity for CB1 and CB2 receptors12 with activation of the former accounting for the psychoactivity of these substances.13 While its molecular structure differs only slightly from that of AKB-48 by the addition of ...
Cannabinoid receptor antagonist
The discovery of the endogenous cannabinoid system led to the development of CB1 receptor antagonists. The first cannabinoid receptor antagonist, rimonabant, was described in 1994. Rimonabant blocks the CB1 receptor selectively and it has been shown to decrease food intake and regulate body-weight gain. The prevalence of obesity worldwide is increasing dramatically and has a great impact on public health. The lack of efficient and well-tolerated drugs to cure obesity has led to an increased interest in research and development of cannabinoid antagonists. Cannabidiol, a naturally occurring cannabinoid, is a non-competitive CB1/2 antagonist.